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MORPHOLOGICAL CHANGES IN RED BLOOD CELLS AS A MARKER OF 
OXIDATIVE STRESS IN RHEUMATOID ARTHRITIS AND ANTIOXIDANTS 
AS ADD ON THERAPY TO STANDARD TREATMENT IN REVERSAL OF 
THE CHANGES - A RANDOMIZED, OPEN LABEL, COMPARATIVE PILOT 
STUDY. 
AUTHORS:  Dr.A.Gomathi, Dr.B.Vasanthi,M.D, Institute of Pharmacology Madras 
Medical College, Chennai-3 
ABSTRACT 
AIM: 
To evaluate morphological changes in red blood cells due to oxidative stress in patients 
with Rheumatoid Arthritis and to study the efficacy of Antioxidants(Vitamin C and E) 
as an add on therapy to standard treatment in the management of these patients 
compared to standard treatment alone. 
METHODOLOGY: 
       This was an open label randomised comparative pilot study. In this study 96 patients 
were screened, 60 patients were included. They were randomly divided into 30 each in 
study and control group. Control group received T. Hydroxy chloroquine 400mg OD 
and T. Indomethacin 25 mg BD (standard treatment), study group received standard 
treatment plus T. Vitamin C 500mg + C. Vitamin E 400mg for 8 weeks. They were 
followed for 4 weeks. Improvement of patients was monitored by RBC morphological 
assessment, pain by visual analogue scale, tender joint score, swollen joint score, 
Disease activity score 28, Inflammatory markers (ESR, CRP), and haemoglobin level 
every 4 weeks till 12 weeks.  
RESULTS: 
         All the 60 patients included in this study completed the study. After 8 weeks of 
treatment in the study group there is statistically significant improvement in pain score, 
tender joint score, swollen joint score and DAS score. Similarly, statistically significant 
reduction in inflammatory markers like ESR, CRP and significant improvement in 
Haemoglobin level were seen. In the follow up period the improvement in study group 
was sustained.  
CONCLUSION: 
          RBC morphology as a biomarker of oxidative stress and adding antioxidant to 
regular treatment is cost effective and novel approach to the treatment of Rheumatoid 
arthritis. 
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 Rheumatoid Arthritis, Oxidative Stress, Anti-Oxidants. 
 
       
INTRODUCTION 
Rheumatoid arthritis is a chronic inflammatory symmetrical arthritis 
mostly involving smaller joints with systemic extra articular manifestations 
involving many organs. (1) 
RA is a relatively common disease with prevalence of 1% and more in 
women than men. Peak incidence is between 2nd and 4th decade of life but there is 
no age bar.(2)  Once initiated, the chronic inflammation in the synovial tissue 
causes progressive joint destruction and deformity in the limbs, resulting in 
deterioration of quality of life in the individual.(3) 
      The exact aetiology is not known, but autoimmunity plays a major role in 
the pathogenesis. Some of the environmental factors that probably triggers the 
immune system are cigarette smoke, emission from automobile, radiation and 
products of bacterial and viral infections etc.in a genetically prone person.(4) 
Presence of high level of Nitric oxide (NO) in rheumatoid synovial fluid 
suggest that oxidative stress initiates the destruction of synoviocytes. (5) 
           The marker for oxidative stress like Thioredoxin, the products of lipid 
peroxidation in the synovial fluid are significantly high in RA patients compared 
to other forms of arthritis.(4),(6) The current treatment involves physical rest, anti-
inflammatory agents and Disease Modifying Anti Rheumatoid Drugs 
(DMARDS). This treatment does not arrest the progress of disease. (7)  
Since free radical injury is one of the triggering factor in RA(8) ,addition of 
antioxidant like Vitamin E and vitamin C can be added to the DMARDS to 
achieve better goal in the treatment of RA in future. 
  
 
 
 
 
 
 
 
 
 
 
REVIEW OF                                    
LITERATURE 
LITERATURE REVIEW 
RHEUMATOID ARTHRITIS 
               Rheumatoid arthritis is a common chronic systemic inflammatory 
disease mainly involving smaller joints of hands and also other organ systems. 
The common symptoms include stiffness of joints, pain, swelling in the joints. (2) 
ETIOLOGY: 
      Even though the exact cause for RA remains unknown, autoimmunity plays 
an important role for its progression and chronicity. (9) 
AGE: 
            RA occurs at an age group with increasing prevalence up to the 7th decade 
of life. Even then the most common age group affected are 4th-5th decade of life.(2) 
GENDER: 
          Women are commonly affected than men in the ratio of 3:1. After the 
menopause incidences are equal in both men and women which indicate the role 
of sex hormone in the aetiology.(2) 
RACE: 
RA is present throughout the world in all racial groups. But the prevalence 
is more in Pima Indians in North America (5%) and lower in Black Africans and 
Chinese (0.3%). (2) 
 
GENETICS: 
 The risk for RA increases 9 fold in the presence of positive family history. 
It is more frequently associated with HLA DR4 and HLA DR1 antigen in the 
MHC region. HLA DR4 patients are more prone for erosive joint disease and have 
poor prognosis.(4) 
AUTOANTIBODIES: 
       The commonly associated antibodies in RA are Rheumatoid factor (RF) 
which is an antibody against Fc portion of immunoglobulin and Anticyclic 
citrullinated protein antibodies (ACPA). These antibodies causes synovial 
inflammation through complement pathway. (10) 
SMOKING: 
       Cigarette smoking is the strongest risk factor for ACPA positive and RF 
positive RA. Depending upon the intensity (no of cigarettes/day) and duration of 
smoking, the risk for RA increases. Smoking induces citrullination of some Self 
proteins creating a new epitopes that induce autoimmune reactions. (2) 
SOCIECONOMIC STATUS: 
           People of poor socioeconomic status are more susceptible to RA.(1) 
OCCUPATION: 
        Risk for RA is 20% more in manual labourer than others. Susceptible 
labourer include coalminer, granite workers, fish industry workers, workers 
exposed to silica and other organic solvents.(1) 
INFECTIOUS AGENT: 
Pathogenesis through single infectious etiological agent is not proved. 
However pathogens like Retro virus, EBV, Mycoplasma, Mycobacteria etc. are 
associated with RA as a triggering agent to autoimmune response.(2) 
OXIDATIVE STRESS: 
     The disturbance in equilibrium between free radicals and antioxidant 
defence mechanism produce oxidative stress which induces the Autoimmunity 
and causing inflammation in the joint. (4),(11) 
Various studies indicates that dietary deficiency of Vitamin E, Vitamin C 
selenium, and copper is associated with increased risk of RA.(6),(12) 
PATHOGENESIS:  
The phases of RA inflammation: 
1. Initiation phase of nonspecific inflammation. 
2. Amplification phase resulting from T cell activation. 
3. Promotion of inflammation by activated T cell by stimulating T cell and B cell. 
4. Stage of chronic inflammation with tissue injury. (2),(13) 
PATHOGENESIS OF INFLAMMATORY RESPONSE:  
         Antigen is phagocytosed by antigen presenting cell. This complex is 
presented to T lymphocyte which attaches the antigen to MHC portion of cell wall 
causing its activation. 
      Activated T cell stimulates T cell and B cell production, there by promoting 
further inflammation. 
         Activated T cell produce cytokine which are toxic to tissue and also 
stimulate further inflammation by stimulating macrophages. 
          Activated B cell produce plasma cell leading to production of antibodies. 
The antibodies combines with complement causing accumulation of poly 
morphonuclear leucocytes which release cytokines, oxygen free radicals hydroxyl 
radical causing cellular damage to synovium and chondrocytes.(3) 
           The main reactive oxygen species produced by chondrocytes are nitric 
oxide (NO) and superoxide radical (O2-). The free radicals damage chondrocytes 
and extracellular matrix of articular cartilage and induce inflammation. (11), (14) 
PATHOGENESIS OF RHEUMATOID ARTHRITIS: 
 
MORPHOLOGY:  
          RA causes broad spectrum morphological changes. The synovium of joint 
is thickened oedematous and hyperplastic, transforming its smooth contour to 
bulbous form.  
The characteristic histological findings are, 
1. Synovial cell proliferation and hyperplasia 
2. Increased vascularity due to angiogenesis 
3. Dense perivascular cell infiltrate mainly CD4Tcell, macrophages, plasma cell 
4. Neutrophil and fibrin aggregates on the surface of synovium 
5. Increased osteoclastic activity 
6. Pannus formation 
         Mass of synovium and stroma with granular tissue, fibroblast and 
inflammatory cell grows and erode the cartilage. After destruction of cartilage, 
pannus cause ankylolysis.(9) 
SKIN: 
       Rheumatoid nodules are seen in the extensor surfaces of forearm. They 
present as firm, non-tender, round mass. Microscopically they have a central zone 
of fibrinoid necrosis surrounded by macrophages, granulation tissue and 
lymphocytes.(9) 
 
BLOOD VESSEL: 
             Rheumatoid vasculitis is the dangerous complication of RA. It affects 
medium and small arteries except kidney. By obliterating the end arteries, it results 
in peripheral neuropathy, gangrene and ulcer. Leucocytic vasculitis produce 
cutaneous ulcer, purpura, and nail bed infarct.(9) 
CLINICAL FEATURES: 
ONSET:  
       The clinical course RA is variable. In 50% of cases it occurs gradually with 
initial prodromal symptoms of fatigue, anorexia, and musculoskeletal symptoms 
which last for weeks and months. Involvement of joints occur later. In 10% cases 
it occurs abruptly with rapid onset of polyarthritis.(13) 
ARTICULAR INVOLEMENT:  
      Synovial inflammation causes pain, swelling, tenderness, stiffness and 
limitation of movement. Pain is the common symptom which increases more on 
movement. 
         Joint stiffness >1 hour is characteristic feature of RA. Accumulation of 
synovial fluid, thickened joint capsule, hypertrophied synovium causes joint 
swelling. 
        RA can affect any joint. The joints commonly affected are metacarpo 
phalangeal joint, proximal interphalangeal joint, wrist, ankle, knee 
metatarsophalangeal joint, shoulder, hip, elbow and upper cervical spine. 
       Symmetrical synovitis of PIP and MCP joints of hands and sparing of DIP 
is the characteristic feature of RA. 
       Involvement of upper cervical spine cause atlanto-axial subluxation which 
leads to spinal cord compression and death. 
         Persistent inflammation of joints leads to weakness of ligaments, tendon 
and joint capsule and degradation of cartilage which further leads to characteristic 
deformities like, 
1. Radial deviation of wrist and ulnar deviation of digits with palmar subluxation 
of proximal phalanges. (Z deformity). 
2. Flexion contracture of PIP and extension of DIP (Boutonniere deformity). 
3. Hyper extension of PIP and flexion of DIP (Swan neck deformity). 
4. Eversion of hind foot. 
5. Widening of fore foot and hallux valgus. 
6. Lateral deviation and dorsal subluxation of toes.(15) 
EXTRA ARTICULAR MANIFESTATION:  
1. Rheumatoid nodules 
2. Rheumatoid vasculitis 
3. Ocular involvement – Episcleritis, Scleritis, and keratoconjunctivitis sicca 
4. Heart – Pericarditis, conduction abnormality, aortic valve incompetence 
5. Pleuropulmonary manifestation – Pleural and Pulmonary fibrosis, interstitial 
pneumonitis, Pleuropulmanory nodules 
6. CNS – proliferative synovitis and joint deformities produce neuropathy of 
median, ulnar, radial and anterior tibial nerve. 
7. Lymph nodes – Enlarged  
8. Muscles – Muscle atrophy, myositis, focal necrosis and rheumatoid nodule 
9. Bone – osteoporosis 
10. Others – Felty syndrome, amyloidosis, secondary Siogren syndrome(16) 
COMPLICATIONS: 
1. Ruptured tendon 
2. Septic arthritis 
3. Ruptured joint ( Baker’s cyst ) 
4. Amyloidosis 
5. Spinal cord compression 
6. Side effects of therapy(16) 
LABORATORY INVESTIGATIONS:  
There is no specific test for the diagnosis of RA. 
1. RHEUMATOID FACTOR (RF):  
It is an antibody specific for Ig M and present in 60-70% of patients with 
RA. It is not a specific test for RA because it is present in other conditions also. 
But it has a prognostic significance. Patient with high titre have more severe 
progression of disease with extra articular manifestations.(13) 
 
2. ANTICYCLIC CITRULLINATED PROTEIN ANTIBODIES(ACCP) : 
        It is present in 50- 80 % of patients with RA. It is the specific test 
(90-95 %) and it is detectable in the very early stage of the disease.(13) 
3. ACUTE PHASE REACTANT : 
I)  ERYTHROCTE SEDIMENTATION RATE (ESR): 
It is a nonspecific test and increased in all patients with RA. Its level falls 
in response to therapy and has a prognostic significance 
II) C-REACTIVE PROTEIN (CRP): 
Increased CRP level indicates the severity of disease activity and prognosis 
of joint damage. (13) 
4. HEMATOLOGICAL ABNORMALITY: 
          Anaemia in RA correlates with the disease activity. The cause of 
anaemia is not correctly understood. Some of the probable cause for anaemia 
in RA are 
1. Anaemia of chronic disease associated with high serum ferritin 
concentration 
2. Poor response to erythropoietin  
3. Drug induced megaloblastic anaemia due to methotrexate and NSAIDS 
administration 
Thrombocytosis is often associated with RA along with anaemia. (17) 
 
 
5. SYNOVIAL FLUID ANALYSIS : 
          Although none of the findings is specific to confirm the presence of 
inflammatory arthritis. The characteristic of synovial fluids are turbid, 
decreased viscosity, increased protein, decreased or normal glucose, decreased 
C3, C4,WBC count >2000/µL.(13) 
6. IMAGING TECHNIQUE : 
1. RADIOGRAPHIC TECHNIQUE: 
 In the early disease radiographic findings are not much useful for 
the diagnosis, they only reveal soft tissue swelling and joint effusion. 
     As the disease progress, radiographic findings shows the extent of 
cartilage destruction and bone erosions and estimate the aggressive 
nature of the disease and shows the impact of therapy. 
Characteristic X-ray findings are 
1. Soft tissue swelling 
2. Periarticular osteoporosis 
3. Decreased joint space 
4. Erosion of bone (13) 
   2. 99Tc Bisphosphonate scan and MRI: 
More valuable in detecting the early inflammatory changes in joint 
tissue, but not routinely indicated. (13) 
 
 
DIAGNOSIS:  
         Diagnosis of RA depends mainly on clinical features and exclusion of other 
inflammatory arthritis. If the initial symptoms are nonspecific, diagnosis becomes 
very difficult in the early stage. 
  Now the diagnosis is mainly based on Revised American college of 
Rheumatology criteria 
The 1987 revised ACR criteria for RA 
1. Arthritis of 3 or more joints: out of 14 joints (Rt or Lt MCP, PIP, elbow, 
ankle, knee, MTP joint )  at least 3 joints have soft tissue swelling,  
2. Morning stiffness; 
Stiffness present in and around the joint which last for at least 1hour before 
maximal improvement 
3. Arthritis of joints in hand – at least one of PIP, MCP, Wrist 
4. Symmetrical arthritis 
5. Rheumatoid nodules – subcutaneous nodules over bony prominence, 
extensor surfaces or juxta articular regions 
      5.  Serum rheumatoid factor 
      6. Radiographic changes – the postero anterior view of hand and wrist joints   
shows erosion or unequivocal decalcification of bone localized to or most marked 
in involved joint. 
Out 7 criteria 4 should be there to classify the patient as having RA.(13) 
DIFFERENTIAL DIAGNOSIS: 
1. Sero negative spondylo arthropathy  
2. Post viral arthritis  
3. Polymyalgia Rheumatica 
4. Acute osteoarthritis(13) 
CLINICAL COURSE AND PROGNOSIS: 
    The course of RA is difficult to predict and variable in individual. Most 
patient will have persistent but fluctuating disease with variable degree of joint 
abnormality and functional disability. 
Within 10 years - 50% have work disability 
Within 20 years –80% will be severely disabled and 20% require joint replacement 
    In RA median life expectancy was shortened by 3- 7years and 2.5 fold 
increased risk of mortality was seen in patient with severe articular disease. 
Prognostic factor indicating more chance of developing joint deformities are 
1. Presence of  >20 inflammed joints 
2. Rheumatoid nodules 
3. Increased ESR 
4. High titre of serum Rheumatoid factor 
5. X- ray evidence of bony erosion 
6. Persistent inflammation 
7. Advanced age at the onset 
8. Presence of comorbid condition 
9. Presence of HLA DR4 (15) 
MANAGEMENT:  
      The main aim of RA management is to improve or maintain functional 
status thereby improving quality of life. The ultimate goal is to achieve complete 
remission of disease. 
  Management of RA involves an interdisciplinary approach. 
1. NON PHARMACOLOGICAL THERAPY 
a. Rest  
b. Weight reduction 
c. Physical therapy 
d. Occupational therapy 
e. Use of assisted device 
2. PHARMACOLOGICAL THERAPY 
a. NSAIDs –Diclofenc, Indomethacin etc. 
b. DMARDS-Methotrexate, Hydroxy chloroquine etc 
c. Corticosteroids -Prednisolone 
d. Biological agent –Etanercept. Anakinra etc 
e. Immunosuppressant – Cyclosporin, Azathioprine 
3. SURGICAL THERAPY (13) 
 
 
PHARMACOLOGICAL THERAPY: 
NSAIDs:  
          They provide symptomatic relief by reducing pain and stiffness. They 
reduce the inflammation by inhibiting COX enzymes which is required for the 
synthesis of prostaglandin a major mediator of inflammation. 
          The NSAIDs commonly used are Indomethacin, Aspirin, Diclofenac, 
Ibuprofen, selective COX 2 inhibitors like Celecoxib, Etoricoxib. (18) 
DMARDS: 
       They have main role in the management of RA. They act by inhibiting 
cytokine, thereby reducing the inflammation, reduction of joint swelling and joint 
erosion and cause fall in acute phase reactant. 
   They should be started singly or in combination before the appearance of 
erosion in bone. Early introduction of DMARDs reduce the mortality rate. The 
beneficial effects are not produced immediately and it takes weeks or months for 
their effect. 
Commonly used DMARDs are Methotrexate, Hydroxy chloroquine, 
Sulphasalazine, other DMARD rarely used are Gold and Pencillamine.(19) 
CORTICOSTEROIDS:  
          The use of Corticosteroids in RA was first identified by Prof. Philip 
Showalter Hench, for which he was awarded the Nobel Prize in 1950. Due to their 
immunosuppressant and anti-inflammatory property, they provide rapid control of 
disease. They are given as early intensive short term regimen to induce remission 
or intramuscular depot preparation to control the disease. 
          They are also used in long term at very low doses 5mg/day or less described 
as physiological dose along with other therapy, as RA patients don’t make normal 
glucocorticoid response to stress. (19) 
BIOLOGICAL AGENT:  
       These are recombinant monoclonal antibodies which bind and inhibit 
cytokines mainly IL-1 and TNF-α thereby preventing further inflammation. 
Compared to other DMARDs they produce quicker response. Biological agents 
are mainly indicated for rapidly progressive disease and severe refractory cases. 
Major drawback of these agents are expensive and serious adverse effect. 
  Commonly used agents are  
1. TNF-α inhibitors – Etanercept, Infliximab, Adalimumab 
2. IL- 1 agents – Anakinra, Abatacept (20) 
IMMUNOSUPPRESSIVE AGENTS: 
       They produce the therapeutic effects similar to DMARDs. Due to variety 
of toxic effects they are indicated in 
1. Patient who have failed therapy with DMARDs and biological agents 
2. Patient with extra articular disease like Rheumatoid vasculitis 
       Commonly used immunosuppressant are Leflunamide, Azathioprine, 
Cyclosporine, and Cyclophosphamide. (20) 
SURGICAL THERAPY:  
   In severely damaged joints surgical procedure are done to relieve the pain 
and to reduce the disability. Commonly used procedures are,  
1. Reconstructive hand surgery – cosmetic improvement and functional 
benefit 
2. Arthroplasty and total joint replacement if larger joints are involved 
3. Open or Arthroscopic synovectomy—mainly for persistent mono arthritis 
of knee joint 
4. Early Tenosynovectomy of wrist  to prevent tendon rupture(16) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
OXIDATIVE STRESS  
Several oxidants are produced during normal course of metabolism in all 
cells including RBCs. In a normal cell there is a balance between pro-oxidant and 
anti-oxidant. This balance can be shifted to pro-oxidants when the production of 
oxygen species is increased greatly or when the level of antioxidants are 
diminished. This state is called “Oxidative Stress”. The free radicals cause damage 
to lipids, proteins, and nucleic acids in cell membrane and plasma lipoproteins. (21) 
 
 
 
 
 
 
 
 
FREE RADICAL:   
           Free radicals are highly reactive molecular species with an unpaired 
electron, which is very short lived before they collide with another molecule and 
abstract or donate an electron to achieve stability. This generate a new radical 
causing a chain reaction. 
 Damage caused to tissues by oxygen radicals is called oxidative damage 
and the factors that protect tissue damages are called Anti-Oxidants.(22) 
 
OXIDANTS – Free 
Radicals 
Anti-Oxidants 
SOURCES:  
ENDOGENOUS: 
1. Respiratory chain in mitochondria 
2. Enzymes like xanthine oxidase, nitric oxidase synthase 
3. Phagocytosis 
4. Transition of metal mediated oxidation 
5. Exercise 
6. Ischemia/reperfusion injury 
EXOGENOUS: 
1. Environmental pollutant 
2. Smoking 
3. Radiation 
4. Ultraviolet light 
5. Toxins including ionising radiation (22) 
 
                     SOURCES OF FREE RADICALS 
TYPES OF FREE RADICALS:  
Oxygen derivatives - common 
 Superoxide anion radical (O2- ) 
 Hydrogen peroxide(H2O2-) 
 Hydroxyl radical (OH- ) 
Nitrogen derivative: 
 Nitro radical (ONOO-) 
 Nitric oxide (NO)(21),(23) 
OXIDATIVE DAMAGE IN CELL: 
          Tissue damage caused by free radical is called oxidative damage which 
cause injury to all important cellular components like membrane lipids, proteins 
and DNA. 
1. Cell membrane lipid  Produce Chronic inflammatory disease like 
Rheumatoid  arthritis 
2. Cell membrane and cytoplasmic proteins  Produce modified protein 
Antibody formation  Autoimmune disease 
3. DNA damage  Mutation  Initiation of cancer 
4. Plasma LDL   Oxidized LDL Engulfed by macrophages  
Atherosclerosis (22) 
 
 
 
 
 OXIDATIVE DAMAGE TO CELL 
    
 
 
 
 
RED BLOOD CELL 
           Red blood cell (RBC) also known as Erythrocytes are formed in 
the myeloid tissue or most commonly known as red bone marrow The formation 
of RBCs is called erythropoiesis. Red blood cells lose nuclei upon maturation, and 
take on a biconcave, dimpled, shape which helps to carry oxygen and to pass 
through capillaries. They are about 7-8 micrometers in diameter 
.                                              
            Normal RBC count 4.5-5.5 million/cu mm in men, 4-4.5 million/cu mm in 
women. The main function is the transportation of oxygen throughout the body 
and to carry out carbon dioxide from tissue. Normal life span of RBC is 120 days. 
Main site of destruction is reticuloendothelial system in spleen and liver.(24)  
STRUCTURE OF RBC:  
       The red blood cell membrane consists of three basic components, lipid 
bilayer, transmembrane (integral) proteins and a cytoskeletal network. The main 
constituent of the lipid bilayer is cholesterol and phospholipid. Cholesterol 
provides flexibility and stability to membrane.  Integral protein embedded in lipid 
bilayer.  Underneath the cell membrane there is a cytoskeleton network. This is 
made up of contractile protein mainly spectrin and actin which maintain the shape 
of RBC.(24) 
         RBCs lack a nucleus (no DNA) and no organelles like mitochondria, 
ribosome and endoplasmic reticulum. Cytoplasm of RBC contains haemoglobin, 
enzymes for glycolytic and HMP shunt pathway, reduced glutathione and vitamin 
C and Vitamin E.(25), (55) 
ERTHROCYTE METABOLISM: 
           In RBCs, ATP is produced through anaerobic glycolysis because it does 
not have mitochondria. This ATP is necessary for maintenance of the biconcave 
shape and flexibility of the cell which allows the cells to squeeze through narrow 
capillaries. Decreased ATP production makes RBCs rigid and fragile and more 
prone to hemolysis.(25), (26) 
       Glucose enters into RBCs through Na independent facilitated diffusion 
(GLUT-1). 80% of the entered glucose is utilized in glycolytic pathway for energy 
production and the remaining 20% glucose enters into HMP shunt pathway to 
produce NADPH with the help of Glucose 6 Phosphate dehydrogenase enzyme. 
This NADPH reduces oxidized glutathione into reduced glutathione which 
protects the RBCs from oxidative damage.(27), (55) 
OXIDATIVE STRESS IN RBC:  
             The RBCs are the first cell to be affected by oxidative stress. As they pass 
through lungs they carry free radicals along with oxygen. The RBCs contain high 
level of cytoplasmic antioxidant both Enzymatic and non-enzymatic in order to 
protect the RBC from deleterious effect of oxidative stress. α-tocopherol, ascorbic 
acid and reduced glutathione are the major endogenous antioxidants.   
α–tocopherol protects the PUFA in the RBC membrane against lipid peroxidation. 
Ascorbic acid, a potent cellular antioxidant protects the cell membrane from 
oxidative damage and also regenerate oxidized α-tocopherol. Reduced glutathione 
in erythrocytes maintain haemoglobin in its native form. It also plays a major role 
in maintenance of membrane thiol group. 
            ROS induced cell membrane damage allows the GSH to pass through the 
membrane causing depletion of GSH in the cytoplasm of RBC. As the 
erythrocytes have no nucleus and ribosome and cannot regenerate GSH and 
enzyme thus becoming vulnerable to oxidative damage.(28) 
              Glutathione maintains the reduced state sulphhydryl group in proteins 
including haemoglobin. Oxidation of sulphhydryl groups leads to the formation 
of denatured protein that forms insoluble masses called as “Heinz bodies” that 
attaches to cell membrane. Oxidation of cell membrane proteins causes rigidity of 
the RBC which are removed from the surface by macrophage in the spleen and 
liver.(29) Higher degree of oxidation ultimately results in hemolysis of RBCs. 
Reticulocytes are visualised in the peripheral blood as polychromatophillic red 
cells which is the cause for macrocytosis.(30), (56) 
     Several Eicosanoid isomers are produced by non-enzymatic free radical 
catalysed oxidation of arachidonic acid. Out of which most characterised 
isoeicosanoids is 8isoPGF2α. They are produced due to lipid peroxidation of 
PUFA by free radicals. Unlike prostaglandin these compounds are initially formed 
esterified in phospholipids, then gets hydrolysed in free form by phospholipase 
which then circulate, get metabolised and excreted in urine. In vivo their 
production is suppressed by Antioxidant but not by COX-1 and CO2 inhibitors. 
           As these Isoprostanes can activate prostanoid receptors they may contribute 
to the pathophysiology of various inflammatory diseases which are insensitive to 
COX inhibitors. Measuring the level of Isoprostanes is considered as the most 
accurate method to assess oxidative stress in-vivo.(31) 
          8 IsoPGF2 α is also a potential mediator of oxidative damage which causes 
injury to RBC cell membrane and produce irregularly contracted crenated RBCs 
and sphreocytes.(32) 
The following are the structural changes in the RBC due to oxidative 
hemolysis 
1.  Irregularly contracted and crenated cells – Due to altered cell membrane 
integrity (33) 
2. Presence of Heinz bodies – Due to Denatured haemoglobin (30) 
3. Bite cells   - Remaining cells after removal of Heinz bodies in the cells by 
spleen(30)  
4. Spherocytes -   spheroidal less disc cell than normal RBC (34) 
5. Macrocytosis – Indicates presence of reticulocytes (30) 
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ANTIOXIDANTS 
DEFINITION:  
       An antioxidant is a stable molecule that interact and neutralize free radicals 
preventing them from causing tissue damage.(35) 
CLASSIFICATION: 
 Endogenous 
 Ubiquinone 
 Uric acid 
 Superoxide dismutase 
 Catalase  
 Glutathione 
 Exogenous 
 Vitamin – E 
 Vitamin – C 
 Carotenoids 
 Lycopene 
 Flavanoids 
 N – acetyl cysteine 
 Lipoicacid 
 Copper 
 Selenium 
 Zinc(35) 
   USES: 
 Cerebrovascular disease 
 Type II diabetes mellitus 
 Alzheimer’s disease 
 Autoimmune disorders 
 Essential hypertension 
 Cardiovascular disease 
 Osteoarthritis 
 Peptic ulcer (35) 
 
 
 
 
 
 
 
 
 
 
 
ASCORBIC ACID (VITAMIN C) 
 A Water soluble vitamin 
 Important essential nutrient 
STRUCTURE 
 
HISTORY 
Vitamin C was isolated by Joseph Svierbely, Albert Szent Gorgyi, and Charles 
Glenking.(36) 
ACTIVE FORM: 
 Dihydroascorbic acid (DHA) 
 Ascorbic acid (AA) (36) 
DIETARY SOURCES 
PLANT SOURCES 
 Indian goose berry 
 Chilli pepper 
 Guava 
 Black currant 
 Red pepper 
  
 
 
 Lemon 
 Orange 
 Broccoli 
ANIMAL SOURCE 
 Lamb brain 
 Chicken liver 
 Calf liver (36) 
BIOSYNTHESIS 
 Vitamin C  is an essential nutrients for human beings 
 Plants and some animals can synthesize their own vitamin C (36) 
DAILY REQUIREMENTS 
Adults – 75 -90 mg/day 
Lactating mother – 105 mg/day 
Pregnant women – 85 mg/day (36) 
PHARMACOKINETICS 
 Absorption takes place by simple diffusion, active transport 
 Excessive intake reduces its absorption(37) 
DRUG INTERACTIONS 
 Improves the absorption of iron   
 Due to its reducing property, interferes with the laboratory test for urine 
glucose  
 High dose reduces effect of oral anti-coagulants 
 Reduces copper , pyridoxine , cyanocobalamine metabolism (37) 
FUNCTIONS:  
1. ANTIOXIDANT 
 Effective  antioxidant - reduces oxidative stress by stabilizing the 
ROS by donating the electrons 
 Protects oxidative damage to DNA 
 Synergises with vitamin –E to reduce lipid peroxidation 
 Maintains antioxidant pool by regenerating other antioxidants (37) 
2. ENZYMATIC COFACTOR 
 Helps in synthesis of collagen by translation hydroxylation of proline 
and lysine 
 catalyse ferrochelatase and incorporates iron into protoporphyrin IX 
in formation of heme  
 acts as co-factor in synthesis of carnitine from methionine and lysine 
 Important cofactor in hydroxylation reaction of dopamine and 
serotonin  
 Vital role in adrenal steroid synthesis(37) 
3. METABOLISM OF CHOLESTEROL 
 Cholesterol is routinely transformed into bile acids in the body. For 
this transformation reaction, hydroxyl group is incorporated into 
cholesterol nucleus with the help of vitamin C. 
 By increasing the expression of LDL receptor in the liver it helps in 
LDL degradation(38) 
4. HYPERTENSION 
 It protects the Nitric Oxide from inactivation by ROS and causes 
vasodilatation. 
 Maintains endothelial function 
 Modulate the autonomic nervous system by restoring sympathovagal 
balance and spontaneous baroreceptor activity.(38) 
 4. DIABETES 
 Improves insulin sensitivity by stabilizing peroxynitrate radicals 
 Regenerates other antioxidants and helps in maintaining antioxidant 
pool(38) 
5. ANTI INFLAMMATORY ACTION 
 Vitamin C has both anti-inflammatory and analgesic action 
 Supresses the production of 8isoPGF2α, the first identified isoprostane 
produced by non-enzymatic free radical induced lipid peroxidation.(30) 
6. CATARACT 
 Prevents the oxidative damage of lens protein (39) 
7. CANCER 
 Prevents cancer by inhibiting formation of carcinogenic N nitraso 
compounds(39) 
8. IMMUNITY  
 Found in high concentration in immune cells 
It modulates  
 Lymphocytes and cytokine production 
 Phagocytic activity 
 Cell adhesion molecules of immune cells 
 It has natural anti allergic property(39) 
9. RHEUMATOID ARTHRITIS 
 Effective antioxidant reduces oxidative stress 
 Helps in formation other antioxidant like Vitamin E 
 Anti-inflammatory and analgesic action(30),(56) 
8. MISCELLANEOUS 
 By Improving endothelial function it decrease the atherosclerosis 
formation 
 Promotes wound healing 
 Reduces ferric to ferrous state, thereby increases iron absorption,,(39) 
Deficiency causes 
 Scurvy 
 Bleeding tendencies 
 Gum bleeding 
 Petechiae  
 Ecchymosis 
 Increased keratinisation 
 Weak bones 
 Stunted growth 
 Delayed wound healing 
 Teeth malformation 
 Decreased iron content of body 
 Painful joints(40) 
ADVERSE EFFECTS:  (High dose >2g/day) 
 Mild GI upset 
 Sleep disturbances 
 Rashes 
 Facial flushing 
 Headache 
 Oxalate stones (41) 
USES: 
 Scurvy 
 Common cold 
 To improve iron status of the body 
 Diabetes mellitus 
 Essential hypertension 
 Prolonged leg ulcer, Bed sores 42 
 
VITAMIN E  
 A Fat soluble vitamin 
  Vitamin E available as eight forms (Tocopherol -4 , Tochotrienols -4) 
 Most common active form is alpha tocopherol43 
HISTORY: 
              In 1922, a fat soluble dietary constituent was found for prevention of 
foetal death and sterility in rats and called as Factor S and anti-sterility factor. In 
1936 it was isolated from wheat germ oil and renamed as Vitamin E.(43),(57) 
CHEMICAL STRUCTURE: 
Vitamin E contains chromanyl ring and 
hydroxyl group (which donate a hydrogen atom 
to reduce free radical) and hydrophobic side 
chain (which allows for penetration into 
biological membrane). (44), (58) 
SOURCES: 
 Soya bean oil  Spinach 
 Green leafy vegetables  Sunflower oil 
 Nuts  Cereals 
 Safflower oil  Wheat germ oil 
 Fish  Egg yolk (35) 
 
  
 
 
 
 
 
DAILY REQUIREMENTS: 
New born – 4-5 mg/ day 
Children – 6-11 mg/day 
Adults-15 mg/day (44) 
PHARMACOKINETIC PARAMETERS: 
 In intestine , vitamin E is absorbed along with chylomicrons 
 Metabolised through cytochrome liver enzymes CYP4F2and CYP3 A 
 Excreted in urine and bile(59) 
DRUG INTERACTIONS: 
 Reduces absorption of vitamins A and K 
 Reduces Iron absorption 
 Increases oral anticoagulant effect(58) 
FUNCTIONAL ROLE:  
1. ANTI OXIDANT 
 Acts as a peroxyl radical scavenger, preventing the propagation of free 
radicals by reacting with them to form a tocopherol radical, which will 
further reduced by a hydrogen donor (such as vitamin C) and returns to 
its reduced state. 
 It is present in the cell membranes and inhibits lipid peroxidation.(45) 
 
2. ANTI INFLAMMATORY ACTION 
 Inhibits non-enzymatic free radical catalysed oxidation of arachidonic 
acid, therefore production of iso-prostanes (PGF2α) is suppressed.(30) 
3. METABOLISM OF CHOLESTEROL 
 By inhibiting LDL oxidation prevents their accumulation in arterial 
intima thereby helps in the prevention of atherosclerosis.(46) 
4. ANTI CLOTTING 
 It inhibits vitamin –K dependent carboxylase by attaching to thiol group 
(46) 
5. ANALGESIC ACTION 
 It has central analgesic action by reducing central pain processing 
(↓ Nitric oxide) (46) 
6. DIABETES 
 Synergistic with vitamin – C 
 Insulin resistance is improved by increasing tyrosine kinase activity(46) 
7. RHEUMATOID ARTHRITIS 
 Protect the cell membrane from free radical injury and provide anti-
inflammatory action  
 Uncouple joint inflammation and joint destruction 
 Provide analgesic action by central mechanism(↓NO)(30),(47) 
 
 
DEFICIENCY SYMPTOMS: 
 RBC deformation 
 Myopathies 
 Decreased immunity 
 Retinal changes 
 Spinocerebellar ataxia 
 Neuropathies (48) 
USES  
 Type II diabetes  Essential hypertension 
 Post herpetic neuralgia  Pregnancy induced hypertension 
 Osteoarthritis  Rheumatoid arthritis 
 Haemolytic disease  Intermittent claudication 
 Benign breast tumour  Nocturnal leg cramps 
 Sterility  Recurrent abortion 
 Systemic lupus Erythematosis  Atherosclerosis (49),(50) 
ADVERSE DRUG REACTIONS: 
 Vomiting  
 Flatulence 
 Abdominal pain  
 Loose stool (51) 
INDOMETHACIN  
 It is an NSAID drug 
 Indole acetic acid derivative 
MECHANISM OF ACTION: 
 Non  selective inhibitor of cyclooxygenase 
  inhibits both COX1 and COX252 
PHARMACOKINETICS: 
 Absorbed orally 
 Metabolised in liver and excreted in urine 
 90% bound to plasma proteins 
 T1/2 2-5 hr(52) 
DOSE:  20-50mg BD-QID 
ADVERSE EFFECT: 
 Gastric irritation, nausea, anorexia, bleeding, diarrhoea 
 Frontal headache ,dizziness, ataxia, hallucination, depression, confusion 
 Hypersensitivity reaction, Rash, Leucopenia (52) 
 
 
 
CONTRAINDICATIONS: 
 Machinery operators 
 Driver 
 Epileptics 
 Psychiatric disorder(52) 
USES: 
 Rheumatoid arthritis, Gout, Ankylosing spondylitis 
 Bartter syndrome 
 Malignancy associated fever 
 Medical closure of PDA (52) 
 
 
 
 
 
 
 
 
 
 
HYDROXY CHLOROQUINE  
 4 amino quinoline derivative of antimalarial drug 
 Induce remission in 50%of patients with RA 
MECHANISM OF ACTION: 
 Exact mechanism not known 
 Suppress the T Lymphocyte response to mitogen  
 Decrease the leucocyte chemotaxis 
 Stabilize the lysosomal enzyme 
 Inhibition of DNA and RNA synthesis (52) 
PHARMACOKINETICS: 
 Orally absorbed 
 High affinity for nuclear chromatin and melanin and is concentrated in 
spleen , lung liver, skin, kidney 
 50% plasma protein bound 
 T1/2  3-10 days (53) 
DOSE: 
400mg/day for 4-6weeks followed by 200mg/day for maintenance 
ADVERSE EFFECT: 
Common: 
      Anorexia, nausea, vomiting, itching, difficulty in accommodation 
Long term: 
      Corneal deposit, loss of hearing, retinal damage, Photo allergy 
Parenteral; 
          Convulsion, hypotension, arrhythmia (53) 
USES: 
 Malaria  
 Rheumatoid arthritis 
 Lepra reaction 
 Infectious mononucleosis 
 Extra intestinal amoebiasis (53) 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
OBJECTIVES 
 
OBJECTIVE 
AIM: 
To study the efficacy of Vitamin C and Vitamin E in Rheumatoid Arthritis. 
PRIMARY OBJECTIVE: 
           To evaluate morphological changes in red blood cells due to oxidative 
stress in patients with Rheumatoid Arthritis and to study the efficacy of 
Antioxidants (Vitamin C and E) as an Add on therapy to standard treatment in the 
management of these patients compared to standard treatment alone. 
SECONDARY OBJECTIVE: 
     Clinical improvement of patient by measuring painful joint score, swollen 
joint score, tender joint score. 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
                                                                                 
METHODOLOGY 
METHODOLOGY 
 The study was conducted in patients with Rheumatoid arthritis, diagnosed 
within 1 year and now attending outpatient department of Rheumatology, Rajiv 
Gandhi Government General Hospital, Chennai. 
Study design: 
 A randomized, open label, prospective, interventional, comparative, 
parallel group pilot study. 
Study population:  
        Adult patients with Rheumatoid Arthritis diagnosed based on American 
college of Rheumatology criteria. 
Study center: 
Institute of Pharmacology, Madras Medical College & Institute of 
Rheumatology, Rajiv Gandhi Government General Hospital, Chennai. 
Study period: 
August 2014-March 2015 
Study duration: 
Treatment period of 8 weeks and     
Post treatment follow up period of 4 weeks per patient. 
 
 
Sample size: 
60 patients (Control group - 30, study group - 30). 
Inclusion criteria: 
 Age: 40-70 years 
 Sex-both genders 
 Patients diagnosed as Rheumatoid Arthritis based on American college of 
association criteria. 
 Patients willing to give written informed consent 
Exclusion criteria:  
 Arthritis incompatible with RA by ACR criteria 
 Patient on oral  and parenteral corticosteroids 
 Pregnant and lactating women 
 Patients with co-existing liver disease, heart disease, dyslipidaemia or 
malignancy 
 Patients with Haematological disorders 
Study procedure: 
The study was conducted after obtaining the approval from Institutional 
Ethics Committee, Madras Medical College and it was done in accordance with 
declaration of Helsinki and Good Clinical practice (GCP) guidelines.  
Patients diagnosed with Rheumatoid arthritis attending the Outpatient 
department, Institute of Rheumatology Madras Medical College and Rajiv Gandhi 
Government General Hospital, were explained about the study purpose, procedure 
and benefits of the study.   
Written informed consent was obtained from those subjects who are willing 
to participate in the study in the prescribed format in regional language prior to 
performance of any study related procedures. If the patients were illiterate, left 
thumb Impression   was obtained. This was done in the presence of an impartial 
witness. 
The demographic details of the patients were obtained and recorded. 
Patients were screened by History, General and Systemic examinations and lab 
investigations.  Patient who fulfil the inclusion and exclusion criteria were 
enrolled and Randomized into either study group or standard group. 
The following lab investigation were performed during screening. 
1. Hb, ESR           
2. Liver function test(LFT )             
3. Renal function test (RFT )          
4. C-Reactive protein  
5. Rheumatoid  factor                                      
6. Chest X ray                       
7.  X ray both hands  
 
 
 
 
RECRUITMENT: 
 96 patients were screened and 30 patients in each group (control and 
study groups) who fulfilled the inclusion and exclusion criteria were 
recruited into the study.  
 No drop-outs of patients in both groups. 
Randomization: 
The enrolled patients were randomized by simple randomization into either 
control group or study group and received the respective therapy. 
 Control group (n=30) –Standard therapy 
 Study group (n=30) – Standard therapy + study drug 
TREATMENT PLAN: 
Control group 
  Standard treatment  
 Tab. Indomethacin 25 mg twice daily and Tab. Hydroxychloroquine 400mg 
once daily  for 8 weeks 
Study group 
      Patients received standard treatment plus capsule Vitamin E 400 mg and 
Tab. Vitamin C 500 mg once daily for 8 weeks 
 
 
60 PATIENTS COMPLETED THE STUDY 
STUDY FLOW CHART 
SCREENED     
96 
Complete medical 
history, Clinical 
examination, 
Biochemical 
investigation 
 
 
 
 
 
 
 
 
 
 
 
  
 STATISTICAL ANALYSIS 
ENROLLED 60 
 
RANDOMIZATION 
CONTROL GROUP 
n=30 
STUDY GROUP 
n=30 
STANDARD TREATMENT +TEST DRUG 
  Tab. Indomethacin 25 mg BD and  
T.Hydroxychloroquine 400 mg OD & 
C.Vitamin E400mg OD & 
 T.Vitamin C 500mg OD   
 
 
C.Vitamin E 400mg OD  
T.Vitamin C 500mg OD 
STANDARD TREATMENT  
 Tab. Indomethacin25 mg BD and 
Tab. Hydroxychloroquine 400mg 
OD   
 
 
 
TREATMENT PERIOD – 8 weeks 
FOLLOW UP -4 weeks 
 
EXCLUDED 36 
 
STUDY VISIT 
SCREENING: 
 Written informed consent obtained. 
 Demographic details obtained. 
 Medical history taken and recorded.  
 Vital signs recorded, General, systemic & local examination done. 
 Laboratory investigations done.  
 Enrollment done. 
VISIT 1  
 Randomization done. 
  Vital signs recorded.  
 Clinical examination of joints was done 
  Pain assessment done by Visual analogue scale. 
 DAS scoring done 
 RBC morphology assessment done. 
 Study drugs were issued for 4 weeks to respective groups. 
 Instructed to return the empty strips during subsequent visit. 
 Patients were instructed to report if any adverse events occur. 
VISIT 2 (end of 4 weeks) 
 Vital signs recorded. 
 Patients were asked to return empty strips to check compliance. 
 Clinical examination of joints was done.  
 Adverse events monitored. 
 Pain assessment done by Visual analogue scale. 
 DAS scoring done. 
 RBC morphology assessment done. 
 Study medication issued for subsequent 4 weeks. 
VISIT 3 (end of 8weeks) 
 Vital signs recorded. 
 Clinical examination of joints was done.  
 Adverse events monitored. 
 Pain assessment done by Visual analogue scale. 
 DAS scoring done. 
 RBC morphology assessment done. 
 
 
VISIT 4 (end of 12weeks) 
 Vital signs recorded. 
 Clinical examination of joints was done.  
 Adverse events monitored. 
 Pain assessment done by Visual analogue scale. 
 DAS scoring done 
 RBC morphology assessment 
ASSESSMENT PARAMETERS  
RBC morphology assessment:   
         1ml of blood was collected from the patients and centrifuged at 3000 rpm 
for 5 minutes. The supernatant was discarded and the packed cells were diluted 
with equal volume of 0.9% normal saline and centrifuged again. The supernatant 
was again discarded and the packed cells were reconstituted as 10% v/v 
suspension with 0.9% normal saline and a drop of this suspension was put on a 
glass slide under a cover slip and studied under High Power Microscope for 
assessment of morphological changes in the red blood cells.                   
               Under high power microscope 100 cells are seen in the centre of field 
and the number of abnormal cells were counted, then number of percentage of 
abnormal cell was noted in both the groups. 
     Differences in the percentage of abnormal cells before and after treatment is 
recorded in both the groups. 
Clinical assessment – based on patient’s symptoms improvement  
                                       Pain – visual analogue scale 
                                       Joint Swelling - based on DAS score 
                                       Joint Tenderness – based on DAS score 
VISUAL ANALOGUE SCALE (VAS): 
 
The Visual Analogue Scale consists of a 10 cm line with 0 at one end representing 
no pain, and 10 at the other end representing the worst pain ever experienced.  
DAS SCORE: 
         DAS 28 is the quantitative measure of Rheumatoid Arthritis disease activity 
and used to monitor the treatment of RA. DAS stands for “Disease Activity 
Scoring” and 28 refers to number of joints that are examined for the assessment. 
DAS is calculated using a formula that includes the number of tender joints, 
swollen joints (28 joints maximum), ESR, and pain by Visual analogue scale. 
Score 1 was given to swelling of single joint and 0 to absence of swelling 
Score 1 was given to tenderness over the joint and 0 to absence of tenderness 
Total number of swollen joint and tender joint was calculated. 
ESR was measured in mm hour 
Pain is measured by VAS by 0-100mm 
DAS28 = 0.56*√(tenderjoints) + 0.28*√(swollenjoints) + 0.70*Ln(ESR)+ 
0.014* VAS 
DAS28 score >5.1 →high disease activity,  
 DAS28 < 3.2    →low disease activity.  
 DAS28 lower than 2.6.→patient in remission  
By comparing a patient’s DAS28 score over multiple time points 
We can see the improvement of response. 
 The EULAR response criteria are defined as follows 
PRESENT 
DAS28 
DAS IMPROVEMENT OVER TIME POINTS 
 > 1.2 0.6-1.2 < 0.6 
<3.2 GOOD 
RESPONSE 
MODERATE 
RESPONSE 
NO RESPONSE 
3.2-5.1 MODERATE 
RESPONSE 
MODERATE 
RESPONSE 
NO RESPONSE 
>5.1 MODERATE 
RESPONSE 
NO RESPONSE NO RESPONSE 
 
 
Lab investigations: 
The following laboratory investigations and assessment of symptoms were 
performed in the patients on screening and at the end of 8 weeks. 
 Haematology - Haemoglobin, ESR 
 Blood glucose 
 Blood urea 
 Serum creatinine 
 Liver function test (SGOT, SGPT) 
 X ray – chest PA view 
 X ray – both hands 
 ECG all leads 
INSTRUCTION TO PATIENTS 
 The patients were instructed clearly regarding the regular intake of the 
medicines. They were given proper advice to report for assessment and drug 
receiving. They were counselled to report if any acute complaints, reactions occur 
Follow up: 
The patients were followed up for a post treatment period of 4 weeks, 
without the study drug for the assessment of symptoms of Rheumatoid arthritis. 
After the completion of 12 weeks of study period, the patients were provided 
appropriate medical care at Institute of Rheumatology Rajiv Gandhi Government 
General Hospital, Chennai. 
 
Adverse events: 
Any adverse event reported by the patient or observed by the physician 
during the study was recorded. The onset of adverse event, causal relationship to 
the study drug and action taken will be recorded. Appropriate medical care was 
provided. 
Withdrawal: 
During the study period the subject was allowed to withdraw his/her 
voluntary consent and opt out of study. Similarly at the discretion of the 
investigator, the subjects were withdrawn from the study if any serious adverse 
event reported by the patient or observed by the physician. 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
        
 
RESULTS 
 
STATISTICAL ANALYSIS 
The obtained data was analysed statistically.  
Distribution of age was analysed using one way ANOVA and Sex 
distribution was analysed by Pearson chi- square test. 
The difference within the groups in pain assessment score, swollen joint 
score, tender joint score and DAS score, RBC morphology was analysed using 
students paired t-test. Similarly the difference between the control and test groups 
was analysed using independent t-test.  
The biochemical investigations were performed at baseline and at the end 
of 4,8,12 weeks. The differences within the groups before and after treatment were 
analysed using student’s paired t- test.  
Statistical analysis was done by using Epi Info software. 
P value <0.05 was considered to be statistically significant. 
 
 
 
 
 
 
 
TABLE-1: AGE DISTRIBUTION 
                                                                           
 
 
 
 
 
 
                        Table – 1 shows the age distribution across the two groups.  
              Most of the patients are in the age group of 31-50 years 
Figure -1: Age Distribution – Graphical representation of Table – 1 
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AGE(YEARS) CONTROL STUDY 
21-30 5 4 
31-40 13 13 
41-50 8 9 
51-60 4 4 
TOTAL 30 30 
TABLE-2: MEAN AGE DISTRIBUTION 
Table 2 shows the mean age distribution between the groups. 
The mean age in the control group is 39.86 and the mean age in the study group 
is 40.43. The difference in mean age between the groups is statistically not 
significant. 
Figure – 2: Mean Age Distribution 
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CONTROL 30 39.86 9.43 
STUDY 30 40.43 8.75 
p-VALUE 0.8091 
TABLE-3: GENDER DISTRIBUTION 
 
 
 
 
 
 
                    Table – 3 shows the gender distribution between the groups. 
 Females outnumber males in both the groups. There is no statistical significance 
in gender distribution between the two groups. 
Figure – 3: GENDER DISTRIBUTION 
Table – 3    Graphical representation of gender distribution 
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GROUP 
MALE FEMALE TOTAL 
N % n %   N % 
CONTROL 7 23 23 76 30 100 
STUDY 6 20 24 80 30 100 
 p-VALUE 1.0 
TABLE-4: VAS PAIN SCORE: 
 
GROUPS DAY 0 AT THE END OF 8 
WEEKS 
p value 
MEAN  SD MEAN SD 
CONTROL 7.06 1.26 6.30 0.915 
 
0.14 
STUDY 6.90 0.923 3.06 0.97 0.001 
p value 1.0 0.042 
 
                                              
                                              Table 4 shows VAS score, 
 
On comparing the two groups, 
              There is statistically no significant change in the control group (p = 0.14). 
In the study group the reduction of VAS score at the end of 8 weeks is significant 
(p=0.001). 
             The difference between the control and study groups on day 0 (p = 1.0) is 
statistically insignificant. At the end of 8weeks statistically significant (p=0.042) 
reduction in pain score is noted in the study group. 
 
 
  
 
Figure 4: VAS PAIN SCORE 
 
 
 
                           Figure 4 is the graphical representation of Table 4. 
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TABLE-5: TENDER JOINT SCORE: 
 
 
GROUPS DAY 0 AT THE END OF 8 
WEEKS 
p value 
MEAN  SD MEAN SD 
CONTROL 14.2 3.82 12.06 3.32 
 
0.06 
STUDY 14.6 4.04 3.06 0.97 0.0001 
p value 0.07 0.0001 
 
                              
                                    Table 4 shows Tender joint score. 
 
On comparing the two groups, 
             There is statistically insignificant change in the control group (p = 0.06). 
At the end 8 weeks the study group showed significant reduction of Tender joint 
score (p=0.0001). 
           The difference between the control and study groups on day 0 is statistically 
insignificant (p = 0.07).   There is statistically significant reduction (p=0.0001) in 
tender joint score is noted in study group at the end of 8 weeks. 
 
  
FIGURE 5: TENDER JOINT SCORE 
 
 
 
                      Figure 5 is the graphical representation of Table 5. 
 
 
 
 
 
14.2
14.6
12.06
3.06
0
2
4
6
8
10
12
14
16
Control Study
TE
N
D
ER
 J
O
IN
T 
SC
O
R
E
Baseline 8 weeks
TABLE-6: SWOLLEN JOINT SCORE: 
 
GROUPS DAY 0 AT THE END OF 8 
WEEKS 
p value 
MEAN  SD MEAN SD 
CONTROL 7.73 2.46 6.03 1.73 
 
0.121 
STUDY 7.66 2.76 2.56 1.59 0.001 
p value 0.927 0.0001 
 
                                   
                                            Table 4 shows swollen joint score, 
On comparing the two groups, 
           There is statistically no significant change in the control group (p = 0.121), 
but in the study group there is significant reduction of swollen joint score 
(p=0.001) at the end of 8weeks is noted. 
             The difference between the control and study groups on day 0 (p = 0.927) 
is insignificant.  After 8 weeks statistically significant reduction (p=0.0001) in 
swollen joint score is noted in the study group. 
 
 
 
  
FIGURE 6: SWOLLEN JOINT SCORE 
 
 
 
                               Figure 6 is the graphical representation of Table 6. 
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TABLE-7: DAS SCORE: 
 
GROUPS DAY 0 AT THE END OF 8 
WEEKS 
p value 
MEAN  SD MEAN SD 
CONTROL 5.39 0.18 4.80 0.15 
 
0.42 
STUDY 5.26 0.2 3.10 0.39 0.001 
p value                0.558 0.032 
 
                                
                                         Table 7 shows DAS score, 
          On comparing the two groups, there is statistically no significant change in 
the control group (p = 0.42), but in the study group reduction of DAS score at the 
end of 8 weeks is significant (p=0.001). 
         The difference between the control and study groups on day 0 is insignificant 
(p=0.558).  After 8 weeks statistically significant (p=0.032) reduction in DAS 
score is noted in the study group. 
          After 8 weeks DAS score in study group is 3.1 and the reduction from base 
line is 2.16 which indicates good response to antioxidant treatment. In the control 
group the DAS score reduction is only 0.59 which indicates poor response to 
standard treatment. 
  
 
FIGURE 7: DAS SCORE 
 
 
                                 Figure 7 is the graphical representation of Table 7. 
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TABLE-8: MEAN ESR 
GROUPS DAY 0 (mm/hr) AT THE END OF 8 
WEEKS (mm/hr) 
% 
REDUCTION 
FROM 
BASELINE 
p value 
MEAN  SD MEAN SD 
 
CONTROL 27.27 2.75 25.3 0.915 
                          
7% 
 
0.06 
STUDY 28.20 4.51 12.06 0.97 57% 0.0001 
p value 0.337 0.001 
  
                          
                                                     Table 8 shows mean ESR 
 
            On comparing the two groups, there is statistically no significant change 
in the control group (p = 0.06) but in the study group the reduction in the ESR at 
the end of 8 weeks is statistically significant (p=0.0001) 
           The difference between the control and study groups on day 0 is 
insignificant (p =0.337).  After 8 weeks statistically significant reduction in ESR 
(p=0.0001) is noted in the study group. 
 
 
TABLE -8A : PERCENTAGE REDUCTION OF ESR 
 
 
Figure 8: MEAN ESR 
                           
                         Figure 8 is the graphical representation of Table 8. 
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STUDY 
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PERCENTAGE CONTROL 
GROUP 
PERCENTAGE  
<5 2 13% 21 70% 
5 to 10 4 23% 2 7% 
10-15 14 47% 0 0 
15-20 9 30% 0 0 
OTHERS(same
/ increase) 
1 3% 7 23% 
TABLE-9: C-REACTIVE PROTEIN 
 
MEAN CRP BASE LINE AT THE END OF 8 
WEEKS 
NO OF 
PATIENTS 
% NO OF 
PATIENTS 
% 
CONTROL >6 30 100 25 83 
<6 0 0 5 17 
STUDY >6 30 100 3 10 
<6 0 0 27 90 
 
                        Table 4 shows CRP, between study and control groups 
 
              On comparing the two groups, at the end of 8 weeks 90% of patients in 
the study groups shows <6 value of CRP. But in the control groups only 17% of 
patients shows reduction of CRP to <6 value. 
 
 
 
 
FIGURE-9: C-REACTIVE PROTEIN 
 
   
 
                            Figure 9 is the graphical representation of Table 9. 
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TABLE-10: % OF ABNORMAL RBC 
GROUPS PERCENTAGE AT 
BASE LINE 
PERCENTAGE 
AT THE END OF 8WEEKS 
P 
VALUE 
MEAN SD MEAN SD 
CONTROL 80.83% 15.2 68.12% 12.32 0.43 
STUDY 80.86% 16.7 5.32% 0.42 0.0001 
 
      Percentage of abnormal RBCs in both groups at the base line was 
approximately 80%. After 8 weeks it was reduced to 68.12% in the control group 
but in the study group it was greatly reduced to 5.32%. 
FIGURE – 10: PERCENTAGE OF ABNORMAL RBCs 
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TABLE-11 : MEAN HAEMOGLOBIN 
GROUPS DAY 0(gm/dl) AT THE END OF 8 
WEEKS(gm/dl) 
p value 
MEAN  SD MEAN SD 
CONTROL 9.32 0.39 9.38 0.23 
 
0.22 
STUDY 9.36 0.69 10.86 0.35 0.042 
p value 0.162 0.043 
 
 
                                  Table 11 shows mean haemoglobin 
 
         On comparing the two groups the increase in haemoglobin is statistically not 
significant in the control group (p = 0.22). In the study group increase of 
haemoglobin at the end of 8 weeks (p=0.042) is statistically significant. 
        The difference between the control and study groups on day 0 (p = 0.162) is 
statistically insignificant .At the end of 8 weeks statistically significant (p<0.043) 
increase in haemoglobin is noted in the study group. 
 
 
 
 
TABLE 11A: PERCENTAGE INCREASE OF HAEMOGLOBIN 
 
FIGURE-11: MEAN HAEMOGLOBIN 
 
                         Figure 11 is the graphical representation of Table 11. 
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TABLE-12: MEAN SYSTOLIC BLOOD PRESSURE 
GROUPS DAY 0(mmHg) AT THE END OF 8 
WEEKS(mmHg) 
p value 
MEAN  SD MEAN SD 
CONTROL 129.33 2.59 128.2 4.28 
 
0.159 
STUDY 128.13 2.46 120.17 3.34 0.0001 
p value 0.55 0.0001 
 
 
                             Table 12 shows mean systolic blood pressure 
 
On comparing the two groups, 
          There is statistically no significant change in the control group (p = 0.159), 
but in the study group there is reduction of mean systolic BP at the end of 8weeks 
(p=0.001) 
           The difference between the control and study groups on day 0   (p = 0.55) 
is insignificant. After 12 weeks statistically significant reduction (p=0.001) in 
mean systolic BP is noted in the study group. 
 
 
 
  
 
FIGURE-12: MEAN SYSTOLIC BLOOD PRESSURE 
 
 
                                 Figure 12 is the graphical representation of Table 12. 
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TABLE-13: MEAN DIASTOLIC BLOOD PRESSURE: 
 
GROUPS DAY 0(mmHg) AT THE END OF 8 
WEEKS(mmHg) 
p value 
MEAN  SD MEAN SD 
CONTROL 85.13 4.27 83.8 5.19 
 
0.324 
STUDY 84.4 2.9 80.27 2.08 0.001 
p value 0.28 0.001 
 
 
                                    Table 13 shows mean diastolic BP 
On comparing the two groups, 
       There is statistically no significant change in the control group (p = 0.324). 
At the end of 8 weeks the reduction of diastolic BP (p=0.001) is statistically 
significant in the study group. 
        The difference between the control and study groups on day 0   (p = 0.28) is 
insignificant. After8 weeks statistically significant reduction in diastolic BP 
(p=0.001) is noted in the study group. 
 
 
 
  
FIGURE-13: MEAN DIASTOLIC BLOOD PRESSURE: 
 
 
                            Figure 13 is the graphical representation of Table 13. 
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 TABLE14: PERCENTAGE DECREASE IN THE VALUE OF 
PARAMETERS DURING THE STUDY PERIOD 
 
 
INVESTIGATIONS 
% decrease from Baseline 
Value 
Control    
Group 
Study   
Group 
MEAN VAS SCORE 10.76 51.42 
MEAN TENDER JOINT SCORE 15.07 79.04 
MEAN SWOLLEN JOINT SCORE 21.91 66.57 
MEAN DAS SCORE 9.09 30.97 
MEAN ESR 7 57 
CRP (No. of persons with > 6) 16.66 90 
RBC MORPHOLOGY SCORE 12.71 75.56 
MEAN SYSTOLIC BP 0.8 6 
MEAN DIASTOLIC BP 1.7 4.8 
MEAN HAEMOGLOBIN -1.16 -16 
 
 
       
 
TABLE-14A: BIOCHEMICAL INVESTIGATIONS- (STUDY GROUP) 
 
 
INVESTIGATIONS 
STUDY GROUP  
p-VALUE BASELINE 
MEAN 
8 WEEKS 
MEAN 
HEMOGLOBIN (g/dl) 9.36 10.86 0.043 
BLOOD UREA (mg/dl) 25.33 24.14 0.182 
SERUM CREATININE (mg/dl) 0.77 0.77 0.839 
BILI RUBIN(mg/dl) 0.93 0.67 0.142 
SGOT (IU/L) 30.37 30.80 0.636 
SGPT (IU/L) 27.67 26.07 0.108 
 
Table 14Ashows the biochemical investigations mean values done in the study 
group at baseline and 12 weeks. 
Comparison showed that there was no statistically significant difference in the 
biochemical investigation mean value except haemoglobin (p<0.001) 
 
 
 
TABLE-14B BIOCHEMICAL INVESTIGATIONS  
(CONTROL GROUP) 
 
 
 
INVESTIGATIONS 
STUDY GROUP  
p-VALUE BASELINE 
MEAN 
8 WEEKS 
MEAN 
HEMOGLOBIN (g/dl)) 9.32 9.38 0.220 
BLOOD UREA (mg/dl) 27.4 24.87 0.080 
SERUM CREATININE (mg/dl) 0.82 0.75 0.960 
BILI RUBIN(mg/dl) 
0.59 0.67 0.142 
SGOT (IU/L) 29.03 28.40 0.433 
SGPT (IU/L) 30.73 30.67 0.946 
 
 
Table 14B shows the biochemical investigations mean values done in the study 
group at baseline and 12 weeks. 
Comparison showed that there was no statistically significant difference in the 
biochemical investigation mean values. 
TABLE-15: ADVERSE EVENT PROFILE 
 
ADVERSE EVENT CONTROL GROUP (30) 
No. of patients 
STUDY GROUP (30) 
No. of patients 
NAUSEA 5(17%) 4(13%) 
VOMITING 1(3%) 1(3%) 
ABDOMINAL PAIN 4(13%) 2(7%) 
HEAD ACHE 2(7%) 1(3%) 
METALLIC TASTE 1(3%) 0 
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TABLE 15A: INCIDENCE OF ADRs 
 
CONTROL GROUP (30) 
No. of patients (%) 
STUDY GROUP (30) 
No. of patients (%) 
NUMBER OF 
ADRs 
13 (43%) 8(27%) 
 
 
FIGURE 15A: ADVERSE EVENT 
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Figure 16: MEAN VAS PAIN SCORE DURING STUDY AND FOLLOW 
UP PERIOD 
 
 
FIGURE 17: MEAN TENDER JOINT SCORE DURING STUDY AND 
FOLLOW UP PERIOD 
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FIGURE 18: MEAN SWOLLEN JOINT SCORE DURING STUDY AND 
FOLLOW UP PERIOD 
 
 
 
FIGURE 19: MEAN DAS SCORE DURING STUDY AND FOLLOW UP 
PERIOD 
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Figure 20: MEAN ESR DURING STUDY& FOLLOWUP PEROIOD 
 
 
FIGURE 21: MEAN HAEMOGLOBIN DURING STUDY & FOLLOWUP 
PERIOD 
 
 
27.27
26.6
25.3 25.8
28.2
18.3
12.06 12.1
0
5
10
15
20
25
30
BASELINE WEEK 4 WEEK 8 WEEK 12
ES
R
 in
 m
m
 /
 h
r
CONTROL GROUP STUDY  GROUP
9.32
9.34 9.38 9.4
9.36
10.2
10.86 10.9
8.5
9
9.5
10
10.5
11
11.5
BASELINE WEEK 4 WEEK 8 WEEK 12
H
b
 in
 g
/d
l
CONTROL GROUP STUDY  GROUP
FIGURE 22: MEAN % of ABNORMAL RBCS DURING STUDY AND 
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DISCUSSION 
 
DISCUSSION 
              RA is an autoimmune induced chronic inflammatory disease affecting 
mainly joint spaces and various organs. Inspite of the treatment, the disease 
progresses and destroys the joints spaces and various tissues leading to 
deformities.(3) 
              Oxidative stress is one of the important etiological factor in the 
pathogenesis of RA. Therefore adding antioxidant to the regular treatment can 
arrest the disease progress. In this study α-tocopherol and ascorbic acid are added 
to the conventional treatment in RA. 
             Most of the patients with RA have anaemia along with elevate ESR level. 
The cause of anaemia and the type of anaemia was not clearly understood and 
there is no reference regarding the type of anaemia and the cause in RA. (17) 
          RBCs are the first target for oxidative damage caused by free radicals.(54) 
Therefore in this study the RBC morphology was used as a biomarker for 
oxidative stress. ROS causes haemolysis in RBCs which alters the shape and size 
of the RBCs. It also denatures the haemoglobin causing” Heinz bodies”. (32) 
                Crenated edges, Heinz bodies, Spherocytes are some of the 
morphological alteration seen due to haemolysis. The lifespan of RBCs and 
oxygen carrying capacity is diminished as a consequences which leads to anaemia 
and tissue destruction. In this study Vitamin E 400mg and Vitamin C 500mg once 
daily after breakfast was given along with conventional treatment for a period of 
2 months. The follow up period was 4 weeks. 
              The level of oxidative stress was measured by the level of haemoglobin 
and percentage of RBCs haemolysis in these patients, as a biomarker for oxidative 
stress. 
              Clinically the patients were assessed for painful joint, tender joint, and 
swollen joints score and DAS score. The laboratory markers like ESR and CRP 
were also used as a marker for inflammation. 
             Out of 96 patients screened 36 were excluded due to various reasons and 
60 patients were divided into study group 30 patients and control group 30 patients 
by simple randomisation. 
             The majority of patients in this study group were between 31-40 years, 
and out of which women were 76% and men were 24%. The improvement in the 
patients was assessed by pain score, tender joint score, swollen joint score, and 
DAS score. 
            In the control group pain score was slightly reduced (p=0.14) at the end of 
8weeks. In the study group pain score was reduced significantly (p=0.001) at the 
end of study. 
           The tender joint score was reduced in the control (P=0.06) which is not 
significant. In the study group at the end of 8 weeks, the tender joint score was 
reduced to (p=0.0001) which is highly significant. 
          Similarly the swollen joint score was significantly reduced in the study 
group (p=0.001) than the control group (p=0.121) 
          The disease activity score at the end 8 weeks in the study group showed 
significant reduction of (p=0.001) than the control groups (p=0.42). 
          The laboratory markers like ESR was approximately 28mm/hr in both the 
groups initially. At the end of 8weeks the ESR level was reduced to12mm/hr in 
the study group, where as in the control group there was only a slight fall to 
25mm/hr only. 
          The CRP was decreased in nearly 90 % of the patients in the study group to 
<6, where as in the control group only 17% of patients showed reduction. 
         Nearly 80 % of the RBCs in both the group of patients were altered due to 
ROS induced haemolysis having crenated edges, Heinz bodies, spherocytes and 
macrocytosis. Presence of macrocytosis (25-30%) in the blood smear (Normal 
being between 0.5% -1%) indicates reactive erythropoiesis induced by haemolysis 
in RA.(29) 
     After treatment with antioxidants the number of abnormal RBCs in the study 
group was reduced to 5%, and in the control group it was reduced to 68% only. 
The reduction in haemolysis of RBCs is correlated to clinical improvement like 
pain score, joint score, proves the role of ROS in the pathogenesis of Rheumatoid 
arthritis. 
        The haemoglobin level was very much reduced in both the groups with mean 
9.3g/dl initially. At the end of 8 weeks the haemoglobin level was increased to 
10.8gm/dl in the study group and, in the control group it was only 9.38gm/dl only. 
       This proves that anaemia in RA is due to haemolysis caused by oxidative 
damage only not due to decreased erythropoiesis or iron deficiency as mentioned 
in the standard text book.(17) 
         All the patients included in the study group showed slight increase in systolic 
and diastolic blood pressure of 130/85mmHg before the study. At the end of 8 
weeks there was a significant reduction in systolic and diastolic blood pressure of 
120/80mmHg in the study group compared to control groups. 
         There was slight decrease in adverse events like abdominal pain, nausea, and 
vomiting in the study group compared to control group. 
          All the patients in both the groups were followed for the period of 4 weeks. 
During the follow up period all the patients received T. Indomethacin 25mg BD, 
T. Hydroxy chloroquine 400mg OD. At the end of 4 weeks all the tests were 
repeated along with clinical examination. 
           In the control group only mild improvement in the joint score was seen, to 
the same extent as during the study period.  
In the study group the improvement in the joint score and RBC biomarker 
and inflammatory markers was sustained during the follow up period. There was 
no exacerbation of the disease after 4 weeks. 
           The improvement in the RBC morphology was well correlated with the 
clinical improvement in the patient who received antioxidants, which confirms the 
role of ROS in the pathogenesis of Rheumatoid arthritis. 
  
 
 
 
 
 
 
 
 
 
 
 
 
CONCLUSION 
 
CONCLUSION 
In this study, it has been proved that anaemia in RA is due to haemolysis 
caused by free radical injury and not due to defective erythropoiesis. 
Hence RBC morphology was used as a bio-marker of oxidative stress in 
RA. Anti-oxidants like vitamin C and E were added to the regular treatment for 8 
weeks. 
The haemolysis was almost completely arrested along with significant 
clinical improvement which was monitored by various scores. This once again 
proves that role of free radical in the pathogenesis of RA. 
Treatment with antioxidants like Vitamin C and Vitamin E arrested the 
disease progress and has a disease modifying action. It also improved the quality 
of life in patients with RA. 
Therefore, using RBC morphology as a bio-marker for oxidative stress and 
adding antioxidant to the regular treatment is cost effective and novel approach to 
the management of RA. 
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APPENDICES 
 
MORPHOLOGICAL CHANGES IN RED BLOOD CELLS AS A 
MARKER OF OXIDATIVE STRESS IN RHEUMATOID ARTHRITIS 
AND ANTIOXIDANTS AS ADD ON THERAPY TO STANDARD 
TREATMENT IN REVERSAL OF THE CHANGES - A RANDOMIZED, 
OPEN LABEL, COMPARATIVE PILOT STUDY. 
CASE REPORT FORM 
NAME:                                       AGE/SEX       :                PLACE: 
OP No:                                        DIAGNOSIS:   
 
Inclusion criteria:        YES/NO 
 Age - 40 years to 70 years 
 Sex - both genders 
 Patients willing to give written informed consent.  
 Patients diagnosed as Rheumatoid Arthritis based on American college 
association criteria. 
Exclusion criteria:        YES/NO 
 Arthritis incompatible with RA by ACR criteria 
 Patient on oral  and parenteral corticosteroids 
 Pregnant and lactating women 
 Patients with co-existing liver disease, heart disease, dyslipidaemia or 
malignancy 
 Patients with Haematological disorders 
 
Subject initials:       Subject number: 
Subject: Included/Excluded                        Reason if excluded:  
  
Informed Consent Obtained: Yes/No 
CONTROL/ TEST                        : 
Signature of principal investigator 
VISIT 1 
1. Vitals: 
2. Medical History: 
3. General /systemic examination: 
4. Investigations: 
Haematology:       
Hb:                       
Blood Urea:           Blood sugar:           Serum creatinine:       
SGPT:                      SGOT:               
ECG: 
X-ray Hand AP  
X-ray chest PA view: 
5. Visual analogue pain scale: 
6. DAS score 
7. RBC morphological assessment 
VISIT 2 
1. Vitals: 
2. Visual analogue pain scale: 
3. DAS score 
4. RBC morphological assessment 
5. Adverse Events: 
VISIT 3 
1. Vitals: 
2. Visual analogue pain scale: 
3. DAS score  
4. RBC morphological assessment 
5. Adverse Events: 
VISIT 4 
1. Vitals 
2. Visual analogue pain scale: 
3. DAS score  
4. RBC morphological assessment 
 
  
 
Information to Participants 
Title: MORPHOLOGICAL CHANGES IN RED BLOOD CELLS AS A 
MARKER OF OXIDATIVE STRESS IN RHEUMATOID ARTHRITIS 
AND ANTIOXIDANTS AS ADD ON THERAPY TO STANDARD 
TREATMENT IN REVERSAL OF THE CHANGES - A RANDOMIZED, 
OPEN LABEL, COMPARATIVE PILOT STUDY. 
     
Investigator:  
Name of Participant: 
This study is conducted in Rajiv Gandhi Govt. General Hospital, Chennai. You are 
invited to take part in this study. The information in this document is meant to help 
you decide whether or not to take part. Please feel free to ask if you have any 
queries or concern 
THE PURPOSE OF THE STUDY 
Rheumatoid arthritis (RA) is a chronic multisystem disease of unknown cause 
causing persistent inflammatory synovitis, usually involving peripheral joints in 
a symmetric distribution. A growing body of evidence shows that oxidative 
stress plays a key role in the pathogenesis of RA. In this study we want to test 
the morphological changes in red blood cells in oxidative stress of RA and the 
effect of Antioxidants in reversing these changes.  
We have obtained permission from the Institutional Ethics Committee.  
The study design 
All patients in the study will be divided into 2 groups. You will be assigned to 
either of the groups. One group will receive the standard treatment & the other 
group will receive standard treatment + Antioxidants 
Study Procedures 
The study involves evaluation of red blood cell morphology at your initial visit 
and you will be expected to review at the end of 4,8,12 weeks. You will be 
required to visit the hospital thrice during the course of the study. At each visit, 
the study physician will collect about 2 ml of blood for studying red blood cell 
morphology and document any changes from your baseline evaluation.    
In addition, if you notice any adverse events, you have to report it. You will be 
required to return unused study medicines when you report for your scheduled 
visits. This will enable correct assessment of the study results. 
Possible benefits to the participant – Antioxidants with your standard 
medications will reduce oxidative stress and your future risk of developing 
complications due to RA 
 Possible benefits to other people - The results of the research may provide 
benefits to the society in terms of advancement of medical knowledge and/or 
therapeutic benefit to future patients.  
 
 
Confidentiality of the information of the participant 
You have the right to confidentiality regarding the privacy of your medical 
information (personal details, results of physical examinations, investigations, 
and your medical history). By signing this document, you will be allowing the 
research team investigators, other study personnel, sponsors, Institutional Ethics 
Committee and any person or agency required by law like the Drug Controller 
General of India to view your data, if required. The information from this study, 
if published in scientific journals or presented at scientific meetings, will not 
reveal your identity. 
Decision to not participate in the study  
Your decision not to participate in this research study will not affect your 
medical care or your relationship with the investigator or the institution. You 
will be taken care of and you will not lose any benefits to which you are entitled.  
Decision to withdraw from the study once started 
The participation in this research is purely voluntary and you have the right to 
withdraw from this study at any time during the course of the study without 
giving any reasons. However, it is advisable that you talk to the research team 
prior to stopping the treatment/discontinuing of procedures etc. 
The results of this study will be informed to you at the end of the study. 
Signature of Investigator                                              Signature of Participant   
Date                                                                              Date 
 
 
INFORMED CONSENT FORM 
  MORPHOLOGICAL CHANGES IN RED BLOOD CELLS AS A 
MARKER OF OXIDATIVE STRESS IN RHEUMATOID ARTHRITIS 
AND ANTIOXIDANTS AS ADD ON THERAPY TO STANDARD 
TREATMENT IN REVERSAL OF THE CHANGES - A RANDOMIZED, 
OPEN LABEL, COMPARATIVE PILOT STUDY. 
Name of the Participant: 
I _____________________________ have read the information in this form (or it 
has been read to me). I was free to ask any questions and they have been answered. 
I am over 18 years of age and, exercising my free power of choice, hereby give 
my consent to be included as a participant in this study. 
1. I have read and understood this consent form and the information provided to 
me. 
2. I have had the consent document explained to me. 
3. I have been explained about the nature of the study. 
4. I have been explained about my rights and responsibilities by the investigator. 
5. I am aware of the fact that I can opt out of the study at any time without having 
to give any reason and this will not affect my future treatment in this hospital.  
6. I hereby give permission to the investigators to release the information obtained 
from me as result of participation in this study to the sponsors, regulatory 
authorities, Govt. agencies, and IEC.I understand that they are publicly presented. 
7. I have understand that my identity will be kept confidential if my data are 
publicly presented 
8. I have had my questions answered to my satisfaction. 
9. I have decided to be in the research study. 
         I am aware that if I have any question during this study, I should contact the 
investigator. By signing this consent form I attest that the information given in 
this document has been clearly explained to me and understood by me, I will be 
given a copy of this consent document. 
1. Name and signature / thumb impression of the participant (or legal 
representative if participant incompetent) 
Name ___________________ 
Signature/Guardian_________________ Date_______ 
2. Name and Signature of impartial witness (required for illiterate patients): 
Name ______________________ 
Signature_________________   Date_______ 
Address and contact number of the impartial witness: 
Name and Signature of the investigator or his representative obtaining consent: 
Name _____________________ Signature_________________  
Date_______ 
 
 
 
 
 
 
 
